COMMUNIQUÉS West-GlobeNewswire

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
02/02/2026
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
02/02/2026
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, [...]
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
02/02/2026
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses Weight [...]
Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging
02/02/2026
Mount Sinai and BPGbio scientists uncover novel molecular drivers from live brain samples that direct human brain structure and function from early development through aging: Creates a completely new molecular [...]
Groundbreaking therapy for advanced heart failure
02/02/2026
Repairon expands to North America to Accelerate Clinical Trials and Product Development GÖTTINGEN, Germany, Feb. 02, 2026 (GLOBE NEWSWIRE) -- German biotech company Repairon GmbH announced the formation of its fully [...]
Thérapie révolutionnaire pour l’insuffisance cardiaque avancée
02/02/2026
Repairon étend ses activités à l’Amérique du Nord pour accélérer son programme clinique et le développement de ses produits GÖTTINGEN, Allemagne, 02 févr. 2026 (GLOBE NEWSWIRE) -- La société de biotechnologie allemande [...]
Agomab Announces Launch of Initial Public Offering
02/02/2026
ANTWERP, Belgium, February 2, 2026 (GLOBE NEWSWIRE) – AgomAb Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory [...]
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026
Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative [...]
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on structured teaching approaches and stable support environments. With the [...]
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026
REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026
REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
02/02/2026
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas)
02/02/2026
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas) DIJON, France - 02 février 2026 (07h15CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), la société pharmaceutique de [...]
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
02/02/2026
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France - February 2, 2026 (7:15 a.m. CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , the specialty pharmaceutical [...]
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients [...]
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3
02/02/2026
Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase 3 LEAP2MONO, le venglustat, administré par voie orale une [...]
Every Smile Is Special: Sparkling Charms Dental Studio Highlights Sensory-Friendly Pediatric Dental Program for Children With Special Needs in Baltimore
02/02/2026
Baltimore, MD, Feb. 01, 2026 (GLOBE NEWSWIRE) -- Sparkling Charms Dental Studio , a family-owned pediatric dental practice based in Baltimore, highlighted its Sensory-Friendly Pediatric Dental Program, designed to [...]
Arctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug–Device Innovation Platform
02/02/2026
SHANGHAI, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Headquartered in Shanghai, Arctic Vision (Cayman) Limited (“Arctic Vision”), a global ophthalmic company, announced that it has entered into an agreement to acquire the [...]
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
01/02/2026
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental [...]

Pages